• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib.

作者信息

Sideras Kostandinos, Menefee Michael E, Burton Jill K, Erlichman Charles, Bible Keith C, Ivy S Percy

机构信息

Endocrine Malignancies Disease Oriented Group, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA.

出版信息

J Clin Oncol. 2010 Jul 1;28(19):e312-3. doi: 10.1200/JCO.2009.26.4432. Epub 2010 Jun 1.

DOI:10.1200/JCO.2009.26.4432
PMID:20516434
Abstract
摘要

相似文献

1
Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib.一名接受多靶点酪氨酸激酶抑制剂帕唑帕尼治疗的非裔美国女性出现严重的毛发和皮肤色素减退。
J Clin Oncol. 2010 Jul 1;28(19):e312-3. doi: 10.1200/JCO.2009.26.4432. Epub 2010 Jun 1.
2
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.帕唑帕尼治疗进展性、放射性碘难治性、转移性分化型甲状腺癌的疗效：一项 2 期联合研究结果。
Lancet Oncol. 2010 Oct;11(10):962-72. doi: 10.1016/S1470-2045(10)70203-5. Epub 2010 Sep 17.
3
Rapid hair depigmentation in patient treated with pazopanib.接受帕唑帕尼治疗的患者出现快速毛发色素脱失。
BMJ Case Rep. 2018 Aug 23;2018:bcr-2018-224209. doi: 10.1136/bcr-2018-224209.
4
Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.多靶点酪氨酸激酶抑制剂治疗碘难治性甲状腺癌的真实世界疗效和安全性。
Thyroid. 2021 Oct;31(10):1531-1541. doi: 10.1089/thy.2021.0091.
5
Hypopigmentation of the Skin and Hair Associated with Dasatinib Therapy.与达沙替尼治疗相关的皮肤和毛发色素减退
Turk J Haematol. 2024 May 30;41(2):116-117. doi: 10.4274/tjh.galenos.2023.2023.0280. Epub 2023 Sep 12.
6
Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.帕唑帕尼、卡博替尼和凡德他尼在进展性甲状腺髓样癌治疗中的应用，特别关注对高血压的不良反应。
Int J Mol Sci. 2018 Oct 20;19(10):3258. doi: 10.3390/ijms19103258.
7
Kinase inhibitors for refractory thyroid cancers.用于难治性甲状腺癌的激酶抑制剂。
Lancet Oncol. 2010 Oct;11(10):912-3. doi: 10.1016/S1470-2045(10)70226-6. Epub 2010 Sep 17.
8
Capillary and cutaneous hypopigmentation secondary to pazopanib.帕唑帕尼继发的毛细血管和皮肤色素减退。
Med Clin (Barc). 2022 Mar 11;158(5):246-247. doi: 10.1016/j.medcli.2021.05.017. Epub 2021 Jul 3.
9
Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: A multicenter study in the Asian population.手足皮肤反应可预测转移性软组织肉瘤患者使用帕唑帕尼的治疗结果：一项亚洲人群的多中心研究。
Asia Pac J Clin Oncol. 2018 Aug;14(4):353-360. doi: 10.1111/ajco.13029. Epub 2018 Jun 13.
10
Hair depigmentation and vitiligo-like lesions in a leukaemic paediatric patient during chemotherapy with dasatinib.一名白血病患儿在接受达沙替尼化疗期间出现毛发色素脱失和白癜风样皮损。
Acta Derm Venereol. 2012 Mar;92(2):218-9. doi: 10.2340/00015555-1289.

引用本文的文献

1
A Comprehensive Review of Mammalian Pigmentation: Paving the Way for Innovative Hair Colour-Changing Cosmetics.哺乳动物色素沉着综述：为创新型变色毛发化妆品铺平道路。
Biology (Basel). 2023 Feb 11;12(2):290. doi: 10.3390/biology12020290.
2
Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer.放射性碘难治性甲状腺癌的新型治疗方法。
Front Endocrinol (Lausanne). 2021 Jul 15;12:720723. doi: 10.3389/fendo.2021.720723. eCollection 2021.
3
Premature Graying of Hair: Review with Updates.头发早白：最新综述
Int J Trichology. 2018 Sep-Oct;10(5):198-203. doi: 10.4103/ijt.ijt_47_18.
4
Phototoxic Reaction Induced by Pazopanib.帕唑帕尼引起的光毒性反应。
Case Rep Dermatol. 2018 Nov 21;10(3):251-256. doi: 10.1159/000494611. eCollection 2018 Sep-Dec.
5
Rapid hair depigmentation in patient treated with pazopanib.接受帕唑帕尼治疗的患者出现快速毛发色素脱失。
BMJ Case Rep. 2018 Aug 23;2018:bcr-2018-224209. doi: 10.1136/bcr-2018-224209.
6
Hair disorders in patients with cancer.癌症患者的毛发疾病。
J Am Acad Dermatol. 2019 May;80(5):1179-1196. doi: 10.1016/j.jaad.2018.03.055. Epub 2018 Apr 14.
7
Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.接受靶向抗癌药物治疗患者的色素沉着变化：一项系统评价和荟萃分析。
J Am Acad Dermatol. 2017 Nov;77(5):902-910.e2. doi: 10.1016/j.jaad.2017.06.044. Epub 2017 Sep 14.
8
Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer.帕唑帕尼概况及其在治疗上皮性卵巢癌中的潜力。
Int J Womens Health. 2014 Mar 13;6:289-300. doi: 10.2147/IJWH.S49781. eCollection 2014.
9
Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with pazopanib.评估接受辅助放疗联合帕唑帕尼治疗的乳腺癌患者的急性局部区域毒性。
ISRN Oncol. 2012;2012:896202. doi: 10.5402/2012/896202. Epub 2012 Dec 6.
10
Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches.新兴治疗方法治疗晚期甲状腺恶性肿瘤：原理与靶向策略。
Expert Opin Investig Drugs. 2011 Oct;20(10):1357-75. doi: 10.1517/13543784.2011.614230.